Project Grant R01AI185511

Award Date 6/21/24
Completion Date 4/30/29
Dollars Obligated $2.6M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $473,937 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a novel point-of-care liquid biopsy for early detection of sepsis-associated organ damage. The project aims to optimize a microfluidic enrichment and digital PCR assay to detect tissue-derived circulating rare cells...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to unravel the relationships between gut and blood microbial signatures and immune responses in sepsis patients. The $403,750 award to Duke University will support a prospective longitudinal study to integrate gut microbial community profiling, metabolomics, measures of intestinal permeability, and blood microbial signatures with immune...
This $294,244 Project Grant award, funded by the Department of Health and Human Services (DHHS) Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, supports research to identify sepsis phenotypes associated with antibiotic-resistant pathogens. The project aims to leverage machine learning techniques, including large language models applied to clinical notes, to augment electronic health record (EHR) data and define...
This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of a novel monocyte transcriptional state, termed "monocyte substate 1" (MS1), in the immunopathogenesis and patient heterogeneity of sepsis. The 5-year project will apply single-cell RNA...
This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s IMMUNIX platform, a precision medicine endotyping solution for sepsis. The project aims to: 1) validate the IMMUNOSCAN multiplex rapid test and mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the ability to...
This Project Grant award of $186,221 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop personalized sepsis therapeutics for pediatric patients. The key objectives are to: 1) Augment sepsis phenotypes using high-frequency physiologic data to identify additional subtypes and predict disease progression; 2) Retrospectively identify signs of bloodstream infection prior to traditional diagnostic signs...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
This $233,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop improved methods for detecting multi-strain and cryptic clade Clostridioides difficile (C. difficile) infections. The primary objectives are to: 1) Identify combinations of growth conditions and selective pressures to optimize recovery of multiple and cryptic clade C. difficile strains from stool...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $424,223 to the University of Florida to investigate molecular profiles associated with lipid metabolism and gene expression in patients with septic acute respiratory distress syndrome (ARDS). The key objectives are to: 1) Identify novel septic ARDS phenotypes by measuring 15 biomarkers, performing lipidomic...

INTEGRATED HOST-MICROBE METAGENOMICS FOR SEPSIS PATHOGEN SURVEILLANCE, SUBPHENOTYPING AND OUTCOME PREDICTION - SUMMARY SEPSIS IS A LEADING CAUSE OF DEATH IN HOSPITALIZED PATIENTS AND INVOLVES A DYSREGULATED HOST INFLAMMATORY RESPONSE TO INFECTION. DESPITE DECADES OF CLINICAL TRIALS, NO NEW, EFFECTIVE TREATMENTS HAVE BEEN IDENTIFIED, AND MORTALITY RATES REMAIN UNACCEPTABLY HIGH. SEVERAL FACTORS HAVE CONTRIBUTED TO THIS IMPASSE, STARTING WITH THE COMPLEX CHALLENGE OF ACCURATELY DETECTING THE MICROBIAL PATHOGENS PRECIPITATING SEPSIS. HETEROGENEITY ACROSS PATIENT POPULATIONS IS A SECOND KEY BARRIER TO THE DEVELOPMENT OF EFFECTIVE TREATMENT STRATEGIES, GIVEN THAT SEPSIS CAN BE CAUSED BY A BROAD DIVERSITY OF MICROBES, AND IMMUNE RESPONSES VARY WIDELY BETWEEN PATIENTS. IN ADDITION, WHILE DISEASE TRAJECTORIES AND INTERVENTIONAL NEEDS DIFFER DRAMATICALLY BETWEEN INDIVIDUALS, NO PROGNOSTIC TOOLS EXIST THAT ACCOUNT FOR BOTH THE HOST RESPONSE AND PATHOGEN, THE TWO PRIMARY DRIVERS OF SEPSIS PATHOBIOLOGY. HERE WE SEEK TO ADDRESS KEY GAPS IN OUR UNDERSTANDING AND TREATMENT OF SEPSIS BY LEVERAGING BLOOD AND PLASMA SPECIMENS COLLECTED FROM 1563 PATIENTS ENROLLED ACROSS 60 MEDICAL CENTERS IN THE CLOVERS TRIAL, THE LARGEST STUDY OF SEPTIC SHOCK TO DATE. AIM 1 SEEKS TO IDENTIFY KNOWN AND NOVEL PATHOGENS RESPONSIBLE FOR SEPTIC SHOCK USING METAGENOMIC SEQUENCING OF HOST AND MICROBE, A NOVEL CULTURE-INDEPENDENT METHOD FOR STUDYING SEPSIS. AIM 2 WILL COMBINE HOST GENE EXPRESSION AND MICROBIAL METAGENOMIC DATA TO DISCOVER NOVEL SEPSIS SUBPHENOTYPES AND EVALUATE THEIR ASSOCIATIONS WITH CLINICAL OUTCOMES. AIM 3 WILL USE MACHINE LEARNING TO DEVELOP A MULTIOMIC CLASSIFIER THAT PREDICTS SEPSIS MORTALITY BY INCORPORATING HOST TRANSCRIPTOMIC, MICROBIAL METAGENOMIC, AND CLINICAL DATA. TOGETHER, THESE AIMS WILL ACCELERATE OUR UNDERSTANDING OF SEPSIS PATHOGENESIS, AND COULD REDEFINE OUR DIAGNOSTIC, THERAPEUTIC, AND PROGNOSTIC STRATEGIES, ULTIMATELY IMPROVING PATIENT OUTCOMES.

Posted 6/20/24